OPKO Health, Inc. $OPK Shares Acquired by AWM Investment Company Inc.

Key Points

• AWM Investment Company Inc. increased its stake in OPKO Health by 42.3% in Q1 2023, acquiring an additional 550,000 shares to own a total of 1,850,000 shares worth approximately $3.07 million.
• CEO Phillip Frost purchased 675,000 shares at an average price of $1.32, increasing his ownership by 0.32% to a total of around 214.68 million shares valued at $283.37 million.
• OPKO Health reported a loss per share of $0.19 for the last quarter, which was below analysts' expectations, and its revenue decreased by 13.9% year-over-year.

AWM Investment Company Inc. increased its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 42.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,850,000 shares of the biotechnology company's stock after acquiring an additional 550,000 shares during the quarter. AWM Investment Company Inc. owned approximately 0.23% of OPKO Health worth $3,071,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Oak Thistle LLC bought a new stake in shares of OPKO Health in the 1st quarter worth approximately $26,000. GM Advisory Group LLC purchased a new position in OPKO Health during the first quarter valued at $33,000. Cerity Partners LLC purchased a new position in OPKO Health during the first quarter valued at $36,000. Pallas Capital Advisors LLC purchased a new position in OPKO Health during the first quarter valued at $43,000. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 12,417 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Trading Down 2.2%

NASDAQ:OPK traded down $0.03 during midday trading on Friday, hitting $1.35. The stock had a trading volume of 1,624,688 shares, compared to its average volume of 1,965,037. OPKO Health, Inc. has a one year low of $1.11 and a one year high of $2.04. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -5.40 and a beta of 1.40. The stock has a 50-day moving average of $1.35 and a 200 day moving average of $1.44. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.The business had revenue of $156.80 million during the quarter, compared to analyst estimates of $165.74 million. During the same period in the previous year, the business earned ($0.01) EPS. The firm's revenue for the quarter was down 13.9% compared to the same quarter last year. As a group, sell-side analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on OPK. LADENBURG THALM/SH SH upgraded OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. Zacks Research raised OPKO Health from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, OPKO Health has an average rating of "Moderate Buy" and an average price target of $2.75.

Insider Buying and Selling

In related news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the business's stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $1.32 per share, with a total value of $891,000.00. Following the completion of the transaction, the chief executive officer owned 214,676,448 shares of the company's stock, valued at $283,372,911.36. The trade was a 0.32% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 49.69% of the stock is owned by company insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.